Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Uptravi For Injection Generic Name & Formulations
Legal Class
Rx
General Description
Selexipag 1800mcg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution.
Pharmacological Class
Prostacyclin receptor agonist.
See Also
How Supplied
Tabs 200mcg—60, 140; 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg—60; Titration pack—1 (140 x 200mcg tabs) + (60 x 800mcg tabs); Single-dose vial (10mL)—1
Manufacturer
Generic Availability
NO
Uptravi For Injection Indications
Indications
Pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional Class II–III symptoms, to delay disease progression and reduce the risk of hospitalization for PAH, when oral therapy is not feasible.
Uptravi For Injection Dosage and Administration
Adult
Give by IV infusion over 80mins twice daily. For corresponding IV dose based on current dose of Uptravi tabs: see full labeling. Moderate hepatic impairment (Child-Pugh class B), concomitant moderate CYP2C8 inhibitors: reduce Uptravi dose to once daily.
Children
Not established.
Uptravi For Injection Contraindications
Contraindications
Concomitant strong CYP2C8 inhibitors (eg, gemfibrozil).
Uptravi For Injection Boxed Warnings
Not Applicable
Uptravi For Injection Warnings/Precautions
Warnings/Precautions
Discontinue if pulmonary veno-occlusive disease confirmed. Severe hepatic impairment (Child-Pugh class C): avoid. Pregnancy. Nursing mothers: not recommended.
Uptravi For Injection Pharmacokinetics
See Literature
Uptravi For Injection Interactions
Interactions
See Contraindications. Potentiated by moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox, teriflunomide); reduce dosing (see Adults). Antagonized by CYP2C8 and UGT 1A3 or 2B7 inducers (eg, rifampin); increase up to twice the dose.
Uptravi For Injection Adverse Reactions
Adverse Reactions
Headache, diarrhea, nausea, jaw pain, vomiting, pain in extremity, myalgia, flushing, arthralgia, rash, anemia, decreased appetite.
Uptravi For Injection Clinical Trials
See Literature
Uptravi For Injection Note
Not Applicable
Uptravi For Injection Patient Counseling
See Literature
